Move to topTop

TOKYO, JAPAN - September 20, 2019 - Terumo Corporation (TSE: 4543) today announced that a new formulation to treat osteoporosis with high risk of fractures, developed by Asahi Kasei Pharma Corporation, has received approval for manufacturing and sales within Japan*. Terumo has signed a manufacturing contract with Asahi Kasei Pharma, and the upcoming product will be manufactured at Terumo Yamaguchi D&D Corporation.

The formulae, TeriboneTM 28.2㎍, is pre-filled in Terumo's PLAJEXTM syringe. Furthermore, the product is assembled as an auto-injector delivery device for a single use dosage. The unique polymer material of PLAJEX TM and Terumo's leading aseptic-filling technology was highly valued when designing this new product.

"With drug and delivery device collaboration, we are able to provide new therapeutic options to patients. We will further contribute to healthcare, by continuing to partner with pharmaceutical companies and cater to their needs", comments Tetsuya Kumei, Division President of the Alliance Division, General Hospital Company of Terumo Corporation.

 

  • 20190920-01.jpg

    TeriboneTM 28.2㎍ subcutaneous autoinjector

 

  • 20190920-02.jpg

    Polymer Pre-Fillable Syringe PLAJEXTM

  •  

     

 

*Asahi Kasei Pharma Press Release on September 20, 2019: "Approval to manufacture and sell Teribone™ autoinjector"

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Media Contact

Corporate Communication Dept., Terumo Corporation

Contact us

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.

News TOP